DDInter1819 DDInter1901
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Upadacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Upadacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Upadacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Upadacitinib {u} may lead to a major life threatening interaction when taken with {v} Anakinra
Upadacitinib {u} may lead to a major life threatening interaction when taken with {v} Lisocabtagene maraleucel
Upadacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Upadacitinib may lead to a major life threatening interaction when taken with Anakinra
Upadacitinib may lead to a major life threatening interaction when taken with Lisocabtagene maraleucel